These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38403067)

  • 1. Prevalence and mortality prognosis of steatotic liver disease phenotypes.
    Sun Z; Zhou C; Zhang Y; Li P; Guo J; Lian Z; Ji H
    Ann Hepatol; 2024; 29(3):101487. PubMed ID: 38403067
    [No Abstract]   [Full Text] [Related]  

  • 2. [NASH (non-alcoholic steatohepatitis): fatty liver or fatal liver disease?].
    Roeb E
    Zentralbl Chir; 2014 Apr; 139(2):168-74. PubMed ID: 22441997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting Liver-Related Outcomes in Steatotic Liver Disease.
    Younossi ZM
    JAMA; 2024 Apr; 331(15):1274-1275. PubMed ID: 38512225
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial: Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis: An Epidemic that will Boost the Incidence of Cardiovascular Morbidity and Mortality.
    Athyros VG; Doumas M
    Curr Vasc Pharmacol; 2018; 16(3):206-208. PubMed ID: 29598814
    [No Abstract]   [Full Text] [Related]  

  • 5. The Association Between Liver Histology and Cardiovascular Risk: Time to Introduce Steatotic Liver Disease Screening in High-Risk Patient Groups?
    Boutari C; Athyros VG
    Angiology; 2024 Mar; 75(3):205-207. PubMed ID: 37691291
    [No Abstract]   [Full Text] [Related]  

  • 6. Embracing Change: From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease Under the Steatotic Liver Disease Umbrella.
    Noureddin M; Wei L; Castera L; Tsochatzis EA
    Clin Gastroenterol Hepatol; 2024 Jan; 22(1):9-11. PubMed ID: 37848118
    [No Abstract]   [Full Text] [Related]  

  • 7. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study.
    Lazo M; Hernaez R; Bonekamp S; Kamel IR; Brancati FL; Guallar E; Clark JM
    BMJ; 2011 Nov; 343():d6891. PubMed ID: 22102439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis and staging of non-alcoholic fatty liver disease.
    Jepsen P; Grønbæk H
    BMJ; 2011 Nov; 343():d7302. PubMed ID: 22102440
    [No Abstract]   [Full Text] [Related]  

  • 9. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease.
    Cotter TG; Rinella M
    Gastroenterology; 2020 May; 158(7):1851-1864. PubMed ID: 32061595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of fatty liver disease with the metabolic syndrome.
    Machado MV; Cortez-Pinto H
    Expert Rev Gastroenterol Hepatol; 2014 Jul; 8(5):487-500. PubMed ID: 24665862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnosis and therapeutic strategies for non-obese type of non-alcoholic fatty liver diseases].
    Chen HT; Zhou YJ
    Zhonghua Gan Zang Bing Za Zhi; 2020 Mar; 28(3):203-207. PubMed ID: 32306652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toward More Accurate Nomenclature for Fatty Liver Diseases.
    Eslam M; Sanyal AJ; George J
    Gastroenterology; 2019 Sep; 157(3):590-593. PubMed ID: 31158374
    [No Abstract]   [Full Text] [Related]  

  • 13. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.
    Stål P
    World J Gastroenterol; 2015 Oct; 21(39):11077-87. PubMed ID: 26494963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD).
    Önnerhag K; Hartman H; Nilsson PM; Lindgren S
    Scand J Gastroenterol; 2019 Mar; 54(3):328-334. PubMed ID: 30907181
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States.
    Le MH; Devaki P; Ha NB; Jun DW; Te HS; Cheung RC; Nguyen MH
    PLoS One; 2017; 12(3):e0173499. PubMed ID: 28346543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex differences in prevalence and prognosis of steatotic liver disease phenotypes: Biological sex matters.
    Ji H; Cheng S;
    J Hepatol; 2024 Feb; 80(2):e68-e69. PubMed ID: 37619929
    [No Abstract]   [Full Text] [Related]  

  • 17. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
    Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphatase and tensin homolog is a differential diagnostic marker between nonalcoholic and alcoholic fatty liver disease.
    Sanchez-Pareja A; Clément S; Peyrou M; Spahr L; Negro F; Rubbia-Brandt L; Foti M
    World J Gastroenterol; 2016 Apr; 22(14):3735-45. PubMed ID: 27076758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.
    Satapathy SK; Sanyal AJ
    Semin Liver Dis; 2015 Aug; 35(3):221-35. PubMed ID: 26378640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016.
    Kim D; Li AA; Gadiparthi C; Khan MA; Cholankeril G; Glenn JS; Ahmed A
    Gastroenterology; 2018 Oct; 155(4):1154-1163.e3. PubMed ID: 30009816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.